|
1
|
Wang X, Zhang A and Sun H: Power of
metabolomics in diagnosis and biomarker discovery of hepatocellular
carcinoma. Hepatology. 57:2072–2077. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fattovich G, Giustina G, Christensen E,
Pantalena M, Zagni I, Realdi G and Schalm SW: Influence of
hepatitis delta virus infection on morbidity and mortality in
compensated cirrhosis type B. The European Concerted Action on
Viral Hepatitis (Eurohep). Gut. 46:420–426. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El Tayebi HM, Omar K, Hegy S, El Maghrabi
M, El Brolosy M, Hosny KA, Esmat G and Abdelaziz AI: Repression of
miR-17-5p with elevated expression of E2F-1 and c-MYC in
non-metastatic hepatocellular carcinoma and enhancement of cell
growth upon reversing this expression pattern. Biochem Biophys Res
Commun. 434:421–427. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fujino H, Kimura T, Aikata H, Miyaki D,
Kawaoka T, Kan H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, et
al: Role of 3-D conformal radiotherapy for major portal vein tumor
thrombosis combined with hepatic arterial infusion chemotherapy for
advanced hepatocellular carcinoma. Hepatol Res. 45:607–617. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Junttila MR, Puustinen P, Niemelä M, Ahola
R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et
al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia
J and Xu D: CIP2A is overexpressed in gastric cancer and its
depletion leads to impaired clonogenicity, senescence, or
differentiation of tumor cells. Clin Cancer Res. 14:3722–3728.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Côme C, Laine A, Chanrion M, Edgren H,
Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, et al:
CIP2A is associated with human breast cancer aggressivity. Clin
Cancer Res. 15:5092–5100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Basile JR and Czerninski R: The role of
CIP2A in oral squamous cell carcinoma. Cancer Biol Ther.
10:700–702. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang LP, Savoly D, Sidi AA, Adelson ME,
Mordechai E and Trama JP: CIP2A protein expression in high-grade,
high-stage bladder cancer. Cancer Med. 1:76–81. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma L, Wen ZS, Liu Z, Hu Z, Ma J, Chen XQ,
Liu YQ, Pu JX, Xiao WL, Sun HD, et al: Overexpression and small
molecule-triggered downregulation of CIP2A in lung cancer. PLoS
One. 6:e201592011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ren J, Li W, Yan L, Jiao W, Tian S, Li D,
Tang Y, Gu G, Liu H and Xu Z: Expression of CIP2A in renal cell
carcinomas correlates with tumour invasion, metastasis and
patients' survival. Br J Cancer. 105:1905–1911. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang CY, Wei CC, Chen KC, Chen HJ, Cheng
AL and Chen KF: Bortezomib enhances radiation-induced apoptosis in
solid tumors by inhibiting CIP2A. Cancer Lett. 317:9–15. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Z, Ma L, Wen ZS, Cheng YX and Zhou GB:
Ethoxysanguinarine induces inhibitory effects and downregulates
CIP2A in lung cancer cells. ACS Med Chem Lett. 5:113–118. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W,
Liu J and Zhou GB: Cancerous inhibitor of PP2A is targeted by
natural compound celastrol for degradation in non-small-cell lung
cancer. Carcinogenesis. 35:905–914. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pandey MK, Sung B, Ahn KS, Kunnumakkara
AB, Chaturvedi MM and Aggarwal BB: Gambogic acid, a novel ligand
for transferrin receptor, potentiates TNF-induced apoptosis through
modulation of the nuclear factor-kappaB signaling pathway. Blood.
110:3517–3525. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang X, Chen Y, Han QB, Chan CY, Wang H,
Liu Z, Cheng CH, Yew DT, Lin MC, He ML, et al: Proteomic
identification of molecular targets of gambogic acid: Role of
stathmin in hepatocellular carcinoma. Proteomics. 9:242–253. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang J, Chi Y, Zhan XK, Xie GR, Wang ZZ,
Xiao W, Wang YG, Hu JF, Yu H, Yang L, et al: An open-labeled,
randomized, multicentered, phase IIa study for advanced cancer
treatment by gambogic acid injection (THS). J Clin Oncol.
29:e130952011.
|
|
18
|
Chi Y, Wang J, Zhan X, Xie G, Wang Z, Xiao
W, Wang Y, Hu J, Yu H, Yang L, et al: p53 open-label, randomised,
multicentre, phase 2a study of gambogic acid injection (THS) for
treatment of advanced cancer. EJC Suppl. 9:212011. View Article : Google Scholar
|
|
19
|
Yu X, Zhao Q, Zhang H, Fan C, Zhang X, Xie
Q, Xu C, Liu Y, Wu X, Han Q, et al: Gambogenic acid inhibits
LPS-simulated inflammatory response by suppressing NF-κB and MAPK
in macrophages. Acta Biochim Biophys Sin (Shanghai). 48:454–461.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Han QB, Wang YL, Yang L, Tso TF, Qiao CF,
Song JZ, Xu LJ, Chen SL, Yang DJ and Xu HX: Cytotoxic
polyprenylated xanthones from the resin of Garcinia hanburyi. Chem
Pharm Bull (Tokyo). 54:265–267. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Q, Cheng H, Zhu G, Yang L, Zhou A, Wang
X, Fang N, Xia L, Su J, Wang M, et al: Gambogenic acid inhibits
proliferation of A549 cells through apoptosis-inducing and cell
cycle arresting. Biol Pharm Bull. 33:415–420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu XJ, Han QB, Wen ZS, Ma L, Gao J and
Zhou GB: Gambogenic acid induces G1 arrest via GSK3β-dependent
cyclin D1 degradation and triggers autophagy in lung cancer cells.
Cancer Lett. 322:185–194. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng H, Su JJ, Peng JY, Wang M, Wang XC,
Yan FG, Wang XS and Li QL: Gambogenic acid inhibits proliferation
of A549 cells through apoptosis inducing through up-regulation of
the p38 MAPK cascade. J Asian Nat Prod Res. 13:993–1002. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan F, Wang M, Chen H, Su J, Wang X, Wang
F, Xia L and Li Q: Gambogenic acid mediated apoptosis through the
mitochondrial oxidative stress and inactivation of Akt signaling
pathway in human nasopharyngeal carcinoma CNE-1 cells. Eur J
Pharmacol. 652:23–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen HB, Zhou LZ, Mei L, Shi XJ, Wang XS,
Li QL and Huang L: Gambogenic acid-induced time- and dose-dependent
growth inhibition and apoptosis involving Akt pathway inactivation
in U251 glioblastoma cells. J Nat Med. 66:62–69. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yan F, Wang M, Li J, Cheng H, Su J, Wang
X, Wu H, Xia L, Li X, Chang HC, et al: Gambogenic acid induced
mitochondrial-dependent apoptosis and referred to phospho-Erk1/2
and phospho-p38 MAPK in human hepatoma HepG2 cells. Environ Toxicol
Pharmacol. 33:181–190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou J, Luo YH, Wang JR, Lu BB, Wang KM
and Tian Y: Gambogenic acid induction of apoptosis in a breast
cancer cell line. Asian Pac J Cancer Prev. 14:7601–7605. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mei W, Dong C, Hui C, Bin L, Fenggen Y,
Jingjing S, Cheng P, Meiling S, Yawen H, Xiaoshan W, et al:
Gambogenic acid kills lung cancer cells through aberrant autophagy.
PLoS One. 9:e836042014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Su J, Cheng H, Zhang D, Wang M, Xie C, Hu
Y, Chang HC and Li Q: Synergistic effects of 5-fluorouracil and
gambogenic acid on A549 cells: Activation of cell death caused by
apoptotic and necroptotic mechanisms via the ROS-mitochondria
pathway. Biol Pharm Bull. 37:1259–1268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He Y, Ding J, Lin Y, Li J, Shi Y, Wang J,
Zhu Y, Wang K and Hu X: Gambogenic acid alters chemosensitivity of
breast cancer cells to Adriamycin. BMC Complement Altern Med.
15:1812015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y and Zhang Y: Regulation of TET
protein stability by calpains. Cell Reports. 6:278–284. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cohen GM: Caspases: The executioners of
apoptosis. Biochem J. 326:1–16. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Storr SJ, Carragher NO, Frame MC, Parr T
and Martin SG: The calpain system and cancer. Nat Rev Cancer.
11:364–374. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Medina DL, Di Paola S, Peluso I, Armani A,
De Stefani D, Venditti R, Montefusco S, Scotto-Rosato A, Prezioso
C, Forrester A, et al: Lysosomal calcium signalling regulates
autophagy through calcineurin and TFEB. Nat Cell Biol. 17:288–299.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shen M, Schmitt S, Buac D and Dou QP:
Targeting the ubiquitin-proteasome system for cancer therapy.
Expert Opin Ther Targets. 17:1091–1108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ciechanover A: Proteolysis: From the
lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol.
6:79–87. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang J, Zhao Q, Qi Q, Gu HY, Rong JJ, Mu
R, Zou MJ, Tao L, You QD and Guo QL: Gambogic acid-induced
degradation of mutant p53 is mediated by proteasome and related to
CHIP. J Cell Biochem. 112:509–519. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Johnston JA, Ward CL and Kopito RR:
Aggresomes: A cellular response to misfolded proteins. J Cell Biol.
143:1883–1898. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bence NF, Sampat RM and Kopito RR:
Impairment of the ubiquitin-proteasome system by protein
aggregation. Science. 292:1552–1555. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Khanna A, Rane JK, Kivinummi KK, Urbanucci
A, Helenius MA, Tolonen TT, Saramäki OR, Latonen L, Manni V,
Pimanda JE, et al: CIP2A is a candidate therapeutic target in
clinically challenging prostate cancer cell populations.
Oncotarget. 6:19661–19670. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Khanna A, Böckelman C, Hemmes A, Junttila
MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C,
et al: MYC-dependent regulation and prognostic role of CIP2A in
gastric cancer. J Natl Cancer Inst. 101:793–805. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Choi YA, Park JS, Park MY, Oh KS, Lee MS,
Lim JS, Kim KI, Kim KY, Kwon J, Yoon DY, et al: Increase in CIP2A
expression is associated with doxorubicin resistance. FEBS Lett.
585:755–760. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jiao M and Nan KJ: Activation of PI3
kinase/Akt/HIF-1α pathway contributes to hypoxia-induced
epithelial-mesenchymal transition and chemoresistance in
hepatocellular carcinoma. Int J Oncol. 40:461–468. 2012.PubMed/NCBI
|
|
44
|
Zhao D, Liu Z, Ding J, Li W, Sun Y, Yu H,
Zhou Y, Zeng J, Chen C and Jia J: Helicobacter pylori CagA
upregulation of CIP2A is dependent on the Src and MEK/ERK pathways.
J Med Microbiol. 59:259–265. 2010. View Article : Google Scholar : PubMed/NCBI
|
